Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE

Dec 05, 2018 by [Charles E. Geyer, Jr., Chiun-Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andrés Redondo, Hans H. Fischer, William Jacot, Alison K. Conlin, Claudia Arce-Salinas, Irene L. Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John P. Crown, Pia Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie Smitt, Hannah Douthwaite, Stina M. Singel, and Gunter von Minckwitz, on behalf of the KATHERINE investigators ]

KATHERINE is a Phase III study of T-DM1 vs trastuzumab in patients with HER2+ early breast cancer who had residual disease after receiving neoadjuvant trastuzumab containing therapy (some patients also received pertuzumab). These are the primary data from the study which is the first study to include such a high-risk group of patients.

Current View

Receive this presentation and more content via email